Abstract:Background: Chemotherapy-induced nausea and vomiting (CINV) significantly impacts patient's quality of life and treatment adherence. This study investigated the efficacy of Generic Netupitant and Palonosetron tablets (Nykron) with dexamethasone single dose for CINV prophylaxis in patients receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC). Additionally, this approach aligns with the principles of the SHIELD study (Sparing High Efficacy Intervention for Low Dose Dexamethasone), which focuses on maximizing antiemetic effectiveness while minimizing dexamethasone use. Methodology: This multicenter retrospective study evaluates data from patients who received HEC/MEC and were administered a fixed-dose combination of Generic NEPA (Netupitant 300 mg and Palonosetron 0.5 mg tablets, Nykron combi-pack) along with a single dose of dexamethasone (12 mg/8 mg) before chemotherapy. The data were collected from September 2022 till September 2023. Outcomes measured included complete response (no vomiting and no need for rescue medications), complete protection (no significant nausea (<2.5 cm on VAS), no vomiting, and no use of rescue medication), and complete control (no emetic episodes, no rescue therapy, and no nausea [0 cm on VAS]) during the acute phase (0-24 hours) and delayed phase (24-120 hours) post-chemotherapy. Results: The data of 372 patients was evaluated in which breast cancer was the most common cancer with 223 (59.95%) patients for which doxorubicin and cyclophosphamide (192, 51.61%) was the most administered chemotherapy combination. The second most common cancer was gastrointestinal (GI) cancer with stomach cancer in 47 (12.6%), colorectal cancer in 4 (1%), and pancreatic cancer in 2 (0.54%). A total of 360 (96.8%) patients received an HEC regimen across the cycle, while only 5 (1.3%) received an MEC regimen. The regimen demonstrated exceptional efficacy with a 96.9% overall response rate across all cycles. Complete control rates for acute CINV were 92% and 90% for delayed CINV across chemotherapy cycles. Complete response rates remained consistently high (94%-98%) across all cycles and overall phases. Only 3% of patients experienced anticipatory CINV. Conclusions: This dexamethasone-sparing Generic NEPA regimen showed remarkable efficacy in CINV management for HEC/MEC regimen-receiving patients, maintaining high response rates in both acute and delayed across all cycles. These findings indicate a potential paradigm shift in CINV prophylaxis, necessitating further investigation through prospective, randomized controlled trials to validate long-term safety and efficacy.

Efficacy Of Intravenous (Iv) Nepa, A Fixed Nk1/5-Ht3 Receptor Antagonist Combination, For Prevention Of Emesis Following Highly Emetogenic Chemotherapy (Hec).

Efficacy of an Intravenous Formulation of NEPA, a Fixed Combination of Fosnetupitant and Palonosetron, Compared with Oral NEPA Studies in the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV): an Analysis of 1026 Patient Experiences.

Efficacy of intravenous NEPA, a fixed NK<sub>1</sub>/5-HT<sub>3</sub> receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies

A Randomized Phase III Study Evaluating the Efficacy of Single-Dose NEPA, a Fixed Antiemetic Combination of Netupitant and Palonosetron, Versus an Aprepitant Regimen for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC).

Phase Iii Study Of Nepa, A Fixed Combination Of Netupitant And Palonosetron, Versus An Aprepitant Regimen For Prevention Of Chemotherapy-Induced Nausea And Vomiting (Cinv).

Efficacy of NEPA, a Fixed Antiemetic Combination of Netupitant and Palonosetron, Vs a 3‐day Aprepitant Regimen for Prevention of Chemotherapy‐induced Nausea and Vomiting (CINV) in Chinese Patients Receiving Highly Emetogenic Chemotherapy (HEC) in a Randomized Phase 3 Study

Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant

Comparison of netupitant/palonosetron with 5-hydroxytryptamine-3 receptor antagonist in preventing of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation

Comparative effectiveness of netupitant-palonosetron plus dexamethasone versus aprepitant-based regimens in mitigating chemotherapy-induced nausea and vomiting: a meta-analysis of randomized controlled trials

Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis

A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation

Efficacy of Netupitant/Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Conditioning Regimens

Comparing the Efficacy of Fosnetupitant, an NK 1 Receptor Antagonist in CDDP-Based Regimens, With that of Fosaprepitant and Aprepitant: A Retrospective Observational Study

Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis

Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy

Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatment

Dexamethasone-Sparing Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting in Highly and Moderately Emetogenic Chemotherapy: The SHEILD Study

Preventing Chemotherapy-Induced Nausea and Vomiting with Netupitant/palonosetron, the First Fixed Combination Antiemetic: Current and Future Perspective.

Efficacy and safety of netupitant/palonosetron in preventing nausea and vomiting in diffuse large B cell lymphoma patients undergoing R–CHOP chemotherapy

Prevention of Cisplatin-Based Chemotherapy-Induced Delayed Nausea and Vomiting Using Triple Antiemetic Regimens: a Mixed Treatment Comparison.

Efficacy and Safety of Triple Therapy with Aprepitant, Ondansetron, and Prednisone for Preventing Nausea and Vomiting Induced by R-CEOP or CEOP Chemotherapy Regimen for Non-Hodgkin Lymphoma: a Phase 2 Open-Label, Randomized Comparative Trial